District-based CME / Non-CME academic lectures

27 11 2025

Osteoporotic Vertebral Fracture:
Treatment and Prevention

Admin Daniel District-based CME / Non-CME academic lectures

27 November 2025

Dr Sieh Koon-man
Specialist in Orthopaedics & Traumatology
MBBS(HK), MRCSE, FRCSE(Orth), FHKCOS, FHKAM(Orthopaedic Surgery), PDHSMPH(CUHK), MPH(CUHK)

Abstract

Osteoporotic vertebral fractures (OVFs) are common fragility fractures. Treatment focuses on pain management, bracing, and physical therapy, with surgeries like vertebroplasty reserved for severe cases. Prevention relies on calcium, Vitamin D, and anti-osteoporotic medications (e.g., bisphosphonates) alongside fall-prevention strategies.

Dr Sieh Koon-man

Specialist in Orthopaedics & Traumatology
MBBS(HK), MRCSE, FRCSE(Orth), FHKCOS, FHKAM(Orthopaedic Surgery), PDHSMPH(CUHK), MPH(CUHK)

Dr Sieh Koon-man (佘冠文) is a specialist in Orthopaedics and Traumatology operating a private practice in Central, Hong Kong.

10 11 2025

PCSK9 inhibition is still the strongest and safest form of LDL lowering available

Admin Daniel District-based CME / Non-CME academic lectures

10 November 2025

Dr Adrian Cheong Yan Yue
LMCHK (BM BCh University of Oxford), MRCP(UK), FHKAM(Med), FHKCP

Abstract

PCSK9 inhibitor antibodies (e.g., evolocumab, alirocumab) remain among the most potent LDL-lowering therapies available, slashing LDL cholesterol by 50% to 60%. They are primarily reserved for high-risk patients who cannot meet targets with statins or ezetimibe, and they have robust cardiovascular outcomes data proving they prevent heart attacks and strokes.

Dr Adrian Cheong Yan Yue

LMCHK (BM BCh University of Oxford), MRCP(UK), FHKAM(Med), FHKCP
He is a Specialist in Cardiology.

17 07 2025

Advancing the disease management of Atopic Dermatitis in the new era

Admin Daniel District-based CME / Non-CME academic lectures

17 July 2025

Dr Lai Yik Kiu Dominic
MBBS (HKU) , MRCP (UK) , FHKCP, FHKAM (Medicine) , DCH (Lond) , M Sc in Dermatology (Cardiff)

Abstract

Atopic dermatitis (AD) management has shifted from broad, non-specific symptom control to precision medicine driven by targeted biologics (e.g., dupilumab, lebrikizumab, nemolizumab) or a once-daily, oral Janus kinase inhibitor (JAK inhibitors e.g., upadacitinib, abrocitinib). This new era transforms care from temporary relief to disease modification, emphasizing rapid itch reduction and long-term, steroid-sparing remission.

Dr Lai Yik Kiu Dominic

MBBS (HKU) , MRCP (UK) , FHKCP, FHKAM (Medicine) , DCH (Lond) , M Sc in Dermatology (Cardiff)

Dr. Lai Yik Kiu, Dominic is a Specialist in Dermatology and Venereology based in Hong Kong.

12 06 2025

A Cardiologist’s Approach to Manage Cardio-kidney-metabolic (CKM) Syndrome in Primary Care

Admin Daniel District-based CME / Non-CME academic lectures

12 June 2025

Dr. Lo Ka Yip, David
MBChB (CUHK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FACC

Abstract

A Cardiologist’s approach to manage cardio-kidney -metabolic syndrome in primary care. A cardiologist’s approach to managing Cardiovascular-Kidney-Metabolic (CKM) syndrome in primary care focuses on early staging, precise risk calculation, and the aggressive deployment of organ-protective medical therapies. According to the latest comprehensive guidelines, managing CKM syndrome requires a shift from treating isolated risk factors to a coordinated, multi-organ prevention strategy.

Dr. Lo Ka Yip, David

MBChB (CUHK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FACC

Dr. Lo Ka Yip, David is a Consultant Cardiologist based in Hong Kong.

16 05 2025

Update on Cardiac and Hypertension Management

Admin Daniel District-based CME / Non-CME academic lectures

16 May 2025

Dr WONG Man Ho, Ivan
MBBS(HK), MRCP(UK), FHKCP, FHKAM(Medicine), FACC

Abstract

Cardiovascular diseases continue to be a leading cause of morbidity and mortality, underscoring the need for effective management in primary care. This presentation provides physicians with the latest evidence-based updates on cardiac conditions and hypertension.

Key topics include advancements in pharmacological therapies, the role of lifestyle changes, and the importance of personalized treatment plans. We will review recent clinical trials that influence current protocols, discuss novel antihypertensive agents, and explore innovative approaches to heart failure management.

This session aims to enhance early detection and preventive strategies, ultimately improving patient outcomes through collaborative efforts between cardiology and primary care.